Christopher Duncan-Lewis, PhD

Christopher Duncan-Lewis, PhD, is a Senior Scientist I at Scribe Therapeutics, leading a project team in developing the next generation of CRISPR-based therapeutics. Prior to their current role, Christopher worked as an Associate Scientist at 23andMe and completed their PhD in Cell/Cellular and Molecular Biology at the University of California, Berkeley. With experience in various research positions at institutions like Denali Therapeutics, University of Pennsylvania School of Medicine, and Yale University, Christopher has a strong background in genetics, biochemistry, and molecular biology.